Literature DB >> 15862291

Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis.

Edward B Lee1, Lewis Z Leng, Virginia M-Y Lee, John Q Trojanowski.   

Abstract

Immunization against the Abeta peptide reverses the pathologic and behavioral manifestations of Alzheimer's disease in murine models. Since active immunization is associated with an autoimmune meningoencephalitis in a subset of humans, passive transfer of anti-Abeta immunoglobulin is being pursued as a potentially safer alternative. We have identified cases of meningoencephalitis subsequent to peripheral and intracerebral passive immunization of Tg2576 mice. The vasocentric mononuclear infiltrate localized only to brain regions affected by Abeta amyloid deposits suggesting that the inflammatory reaction was Abeta specific. This report indicates that current passive immunization in humans should proceed with careful regard for autoimmune complications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15862291     DOI: 10.1016/j.febslet.2005.03.070

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  19 in total

1.  Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries.

Authors:  M Medecigo; K Manoutcharian; V Vasilevko; T Govezensky; M E Munguia; B Becerril; A Luz-Madrigal; L Vaca; D H Cribbs; G Gevorkian
Journal:  J Neuroimmunol       Date:  2010-05-06       Impact factor: 3.478

Review 2.  Alzheimer's therapeutics: translation of preclinical science to clinical drug development.

Authors:  Alena V Savonenko; Tatiana Melnikova; Andrew Hiatt; Tong Li; Paul F Worley; Juan C Troncoso; Phil C Wong; Don L Price
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

Review 3.  Murine models of Alzheimer's disease and their use in developing immunotherapies.

Authors:  Thomas Wisniewski; Einar M Sigurdsson
Journal:  Biochim Biophys Acta       Date:  2010-05-13

4.  Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy.

Authors:  Allan Wang; Pritam Das; Robert C Switzer; Todd E Golde; Joanna L Jankowsky
Journal:  J Neurosci       Date:  2011-03-16       Impact factor: 6.167

5.  The benefits and limitations of animal models for translational research in neurodegenerative diseases.

Authors:  Mathias Jucker
Journal:  Nat Med       Date:  2010-09-21       Impact factor: 53.440

6.  Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease.

Authors:  Hong-Duck Kim; Kazuki Tahara; J Adam Maxwell; Robert Lalonde; Tatsuya Fukuiwa; Kohtaro Fujihashi; Kent R Van Kampen; Fan-Kun Kong; De-chu C Tang; Ken-ichiro Fukuchi
Journal:  J Gene Med       Date:  2007-02       Impact factor: 4.565

Review 7.  Neuroimmune interactions in Alzheimer's disease-New frontier with old challenges?

Authors:  Stefan Prokop; Virginia M Y Lee; John Q Trojanowski
Journal:  Prog Mol Biol Transl Sci       Date:  2019-10-24       Impact factor: 3.622

Review 8.  Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial.

Authors:  Tyler A Kokjohn; Alex E Roher
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-04       Impact factor: 4.388

Review 9.  Impact of amyloid imaging on drug development in Alzheimer's disease.

Authors:  Chester A Mathis; Brian J Lopresti; William E Klunk
Journal:  Nucl Med Biol       Date:  2007-09-04       Impact factor: 2.408

Review 10.  Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'?

Authors:  Gregory A Jicha
Journal:  Expert Opin Biol Ther       Date:  2009-04       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.